The closing price of Virios Therapeutics Inc (NASDAQ: VIRI) was $0.43 for the day, down -8.45% from the previous closing price of $0.47. In other words, the price has decreased by -$0.0299 from its previous closing price. On the day, 856192 shares were traded.
Ratios:
Our analysis of VIRI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.62 and its Current Ratio is at 11.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 21 ’23 when Pridgen William bought 15,335 shares for $1.30 per share. The transaction valued at 19,992 led to the insider holds 52,045 shares of the business.
Duncan Gregory Scott bought 25,000 shares of VIRI for $31,245 on Aug 17 ’23. The CHIEF EXECUTIVE OFFICER now owns 57,461 shares after completing the transaction at $1.25 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIRI now has a Market Capitalization of 8.28M and an Enterprise Value of 4.97M.
Stock Price History:
Over the past 52 weeks, VIRI has reached a high of $2.42, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 0.4169, while the 200-Day Moving Average is calculated to be 0.9054.
Shares Statistics:
VIRI traded an average of 371.42K shares per day over the past three months and 940.02k shares per day over the past ten days. A total of 18.33M shares are outstanding, with a floating share count of 14.86M. Insiders hold about 22.83% of the company’s shares, while institutions hold 4.47% stake in the company. Shares short for VIRI as of Feb 29, 2024 were 96.2k with a Short Ratio of 0.26, compared to 90.97k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.50% and a Short% of Float of 0.53%.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.04 and a low estimate of -$0.04, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.17 and -$0.37 for the fiscal current year, implying an average EPS of -$0.27. EPS for the following year is -$0.3, with 2 analysts recommending between -$0.28 and -$0.32.
